Efficacy of Yigu versus Aclasta in Chinese postmenopausal women with osteoporosis: a multicenter prospective study.
Li M, Cheng Q, Huo YN, Chao AJ, He L, Xue QY, Xu J, Yan SG, Jin H, Zhang ZL, Lin JH, Jin XL, Xu YJ, Liu F, Xia WB.
Li M, et al.
Arch Osteoporos. 2022 Jan 12;17(1):14. doi: 10.1007/s11657-021-01052-y.
Arch Osteoporos. 2022.
PMID: 35020038
Free PMC article.
Clinical Trial.
INTRODUCTION: Yigu has been approved its bioequivalence to Aclasta. However, the clinical efficacy and safety of Yigu have not been evaluated yet. ...RESULTS: A total of 458 postmenopausal women with osteoporosis were enrolled (n = 227, Yigu; n = 231, Aclasta). The …
INTRODUCTION: Yigu has been approved its bioequivalence to Aclasta. However, the clinical efficacy and safety of Yigu have not been e …